EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact on weight of a Doravirine switch in people living with HIV

Nina Garofoli iD, Philippe Flandre iD, Jean-Paul Vincensini, Quentin Richier iD, Priscille Couture, Karine Lacombe, Gilles Pialoux, Jean-Luc Meynard

HIV Medicine · 2026

DOI: 10.1111/hiv.70123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von Nina Garofoli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hopitaux de Paris Nord, Saint-Antoine Hospital, Paris, France. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Anti-HIV Agents, Triazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Doravirine is among the first‐line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti‐integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we investigated weight variation in PLHIV switching to doravirine.

Methods

A retrospective cohort analysis was conducted in two Parisian hospitals, including all PLHIV switching to doravirine between January 2019 and September 2022. Body Mass Index (BMI) variation was calculated from 48 months before to 36 months after the switch.

Results

Between January 2019 and December 2022, 300 patients were included, with 220 men (73%) and 185 (62%) patients born in France. The main antiretroviral combination before the switch was TAF/FTC/BIC ( n = 47, 16%), and after the switch, doravirine with TDF and 3TC ( n = 202, 67%). Twenty‐eight patients (9.3%) discontinued doravirine after a median duration of 17.5 months. At 12 and 24 months after the switch, the median BMI variation was 0.0 kg/m 2 , and this variation remained unchanged regardless of the pre‐switch treatment. These results were less pronounced in subgroups of patients originating from sub‐Saharan Africa (+0.2 and +0.4 kg/m 2 ) and in women (+0.3 and 0.5 kg/m 2 ).

Conclusion

Switching to doravirine led to a weight stabilisation, without reversal of the previously gained weight. In PLHIV at higher risk of weight gain, there was still a slight increase in BMI after the doravirine switch.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPyridonesAnti-HIV AgentsTriazolesWeight GainDrug SubstitutionBody WeightHumansMaleFemaleRetrospective StudiesAdultMiddle AgedBody Mass IndexFrance

Stichwörter der Autor:innen

BMIDoravirineHIV treatmentswitchweight change

Substanzen

doravirinePyridonesAnti-HIV AgentsTriazoles

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hopitaux de Paris Nord, Saint-Antoine Hospital, Paris, France.
  • INSERM UMR-S1136, Université Sorbonne Paris, Paris, France.
  • Department of Infectious Diseases, Hopitaux de Paris, Tenon Hospital, Paris, France.

ORCID-Profile: Nina Garofoli, Philippe Flandre, Quentin Richier

Zitieren

APA

Garofoli, N., Flandre, P., Vincensini, J. P., Richier, Q., Couture, P., Lacombe, K., Pialoux, G., & Meynard, J. L. (2026). Impact on weight of a Doravirine switch in people living with HIV. HIV Medicine. https://doi.org/10.1111/hiv.70123

Vancouver

Garofoli N, Flandre P, Vincensini JP, Richier Q, Couture P, Lacombe K, et al. Impact on weight of a Doravirine switch in people living with HIV. HIV Medicine. 2026. doi:10.1111/hiv.70123

BibTeX
@article{Garofoli2026,
  author = {Garofoli, Nina and Flandre, Philippe and Vincensini, Jean-Paul and Richier, Quentin and Couture, Priscille and Lacombe, Karine and Pialoux, Gilles and Meynard, Jean-Luc},
  title = {Impact on weight of a Doravirine switch in people living with HIV},
  journal = {HIV Medicine},
  year = {2026},
  doi = {10.1111/hiv.70123}
}
Kostenlos starten →